Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768232 | 0.92 | RAB9A (0.50) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4765227 | 0.88 | ROCK2 (0.47) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4765298 | 0.88 | NPC1 (0.55) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4764960 | 0.87 | ROCK2 (0.50) | ABL1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL4767429 | 0.85 | RAB9A (0.55) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4768415 | 0.84 | HRH3 (0.49) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4772436 | 0.84 | HRH3 (0.52) | ABL1NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL4770989 | 0.83 | SMN1; SMN2 (0.71) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4771974 | 0.83 | CREBBP (0.58) | NPC1HTTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4768282 | 0.81 | CREBBP (0.58) | NPC1HTTRAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | ABL1 970/4885NPC1 2009/4885HTT 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.